Work

Energizing the Search to Target LKB1-Mutant Tumors

Year: 2013

Type: article

Abstract: SUMMARY: LKB1 is the third most frequently mutated gene in non-small cell lung cancer and serves as a master regulator of cell metabolism and polarity across a variety of model organisms. Recent studies are beginning to identify therapeutics that exploit defects associated with LKB1 loss. The work presented here by Liu and colleagues shows that deoxythymidylate kinase is a new potential target in LKB1-deficient tumors and highlights the possibility of a new therapeutic option for this subset of patients with cancer.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-13-0296

Authors: Adam I. Marcus, Fadlo R. Khuri

Institutions: Emory University, Winship Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute